BLUE - bluebird bio, Inc.

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339-499-9300
http://www.bluebirdbio.com

Sector: Healthcare
Industry: Biotechnology
Full-time employees: 479

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nick Leschly	Pres, CEO & Director	814.62k	732.07k	1973
Mr. Jeffrey T. Walsh	Chief Financial & Strategy Officer and Treasurer	568.05k	N/A	1966
Ms. Susanna Gatti High	Chief Operating Officer	16.63k	N/A	1968
Dr. Philip D. Gregory D. Phil.	Chief Scientific Officer	622.15k	N/A	1971
Dr. David M. Davidson M.D.	Chief Medical Officer	554.35k	299.61k	1964

Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Corporate governance

bluebird bio, Inc.’s ISS governance QualityScore as of 1 April 2018 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.